Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer

29 May 2020

Abstract excerpt

Triple negative breast cancer (TNBC) encompasses molecularly different subgroups, with a subgroup harboring evidence of defective homologous recombination (HR) DNA repair. Here, within a phase 2 window clinical trial, RIO trial (EudraCT 2014-003319-12), we investigate the activity of PARP inhibitors in 43 patients with untreated TNBC. The primary end point, decreased Ki67, occured in 12% of TNBC. In secondary end...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32471999
DOI: 10.1038/s41467-020-16142-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancerPMID 32471999Read ↗

Therapeutic Advances and New Directions for Triple-Negative Breast CancerSemantic proximity Read ↗

Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancerSemantic proximity Read ↗

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer.Semantic proximity Read ↗

Poly (adenosine diphosphate‐ribose) polymerase inhibitors in the treatment of triple‐negative breast cancer with homologous repair deficiencySemantic proximity Read ↗

Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and ResistanceSemantic proximity Read ↗

Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?Semantic proximity Read ↗

Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cellsSemantic proximity Read ↗

Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)Semantic proximity Read ↗

Emerging Protein Targets in Triple Negative Breast Cancer: Beyond Conventional TherapySemantic proximity Read ↗

Exploiting DNA repair defects in triple negative breast cancer to improve cell killingSemantic proximity Read ↗

Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspectiveSemantic proximity Read ↗

Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.